Generic Drugs: Global collaboration opportunities

Generic Drugs: Global collaboration opportunities

Regular price $1,250.00 Sale

Key facts, statistics and insights on 160 medium-sized generic manufacturers based in 42 countries!

Collaboration is the key to growth

With the recent economic turmoil affecting many markets around the world, the generic and branded sectors face similar problems.

At one time the generic sector was seen as a valuable way to bring effective products to a wider audience. This, allied to the rising cost of new advanced branded products, led to rapid expansion of the generics sector. Even markets traditionally based in the provision of branded medicines have made moves to increase generic prescribing.

But pressure on health spending is seeing downward pressure on generic prices. With lower margins this is creating pain for generics companies.

SME Generic companies offer focused opportunities

With established markets compromised, where can the industry go? Expansion in the sector has been seen through more partnering, either through outright acquisition to increase market share or through product and marketing licensing. Being bigger and having improved market access is seen as a way of distributing cost and strengthening revenues. While major players such as Teva and Sandoz play an international role, there are a number of established and progressive generic manufacturers worthy of consideration.

Use this report to...

Identify commercial partners to secure new markets, technologies and revenues
Assess merger and acquisition targets
Understand the developing generic industry in key markets worldwide
Profile the competitive environment in the increasingly important medium-sized company sector
Seek out companies manufacturing/marketing similar product lines
Assess the investment potential of these key companies
Find and assess potential partners and acquisition targets with this report
This new report from Espicom is a key resource for the wide assessment of 160 medium-sized generic companies operating in 42 markets worldwide. The report provides an essential and comprehensive evaluation of each company:

Location, establishment and full contact details
Financial information, where available
Products and/or therapy areas
Recent strategic alliances
Delivering the key content you need...
  • Background
A summary of the company's foundation and main business interests
  • Product range
Details of ANDAs approved or products/therapy areas represented
  • Financial
Financial performance or funding data
  • Strategic alliances
Details of significant marketing and supply agreements
  • Contact information
Postal, telephone, fax and website details

About the Author: Generic Drugs: Global Collaboration Opportunities has been researched and written by Espicom editor Ian Platts. In addition to this report, Ian edits the leading newsletter World Generic Markets and has monitored the generics market for over 10 years.

Other reports in the series:
World Generic Market Report
(June 2013) VOLUME I: COMPANY PROFILES & VOLUME II: COUNTRY PROFILES
A complete global analysis of the prospects for markets and companies in this dynamic industry sector
Biosimilar Opportunities in an Evolving Market
(August 2013)
The long awaited promise of biosimilars takes another step to fulfilment with the first approval in Europe of high-value second generation products. But what products can be expected to follow, who is developing them and what are the hot prospects?
Inhalation & Nasal Spray Generic Drugs
(November 2013)
Comprehensive overview of the challenges and opportunities across the respiratory drugs market, and the FDA's new product guidance forgeneric inhalers.


Table of Contents

Contents
Companies In This Report
Company Details In Focus
Argentina
Laboratorios Phoenix
Snapshot
Background
Products
Major Developments
Contact Details
Australia
Alchemia
Snapshot.
Background
Products
Financials
Major Developments
Contact Details
Bangladesh
Beximco Pharmaceuticals.
Snapshot.
Background
Products
Financials
Major Developments
Contact Details
Brazil.
Hypermarcas
Snapshot.
Background
Products
Financials
Major Developments
Contact Details
LAFEPE
Snapshot.
Background
Products
Major Developments
Contact Details
moksha
Snapshot.
Background
Products
Major Developments
Contact Details
Bulgaria
Sopharma
Snapshot.
Background
Products

Financials
Contact Details
Canada
AA Pharma
Snapshot.
Background
Products
Contact Details
BioVectra
Snapshot.
Background
Products
Major Developments
Contact Details
Intellipharmaceutics International
Snapshot.
Background
Products
Financials
Major Developments
Contact Details
Chile
CFR Pharmaceuticals
Snapshot.
Background
Products
Financials
Major Developments
Contact Details
China
Aoxing Pharmaceutical
Snapshot
Background
Products
Financials
Major Developments
Contact Details
China Pharma Holdings
Snapshot.
Background
Products
Financials
Contact Details
Rxmidas/GRMIDAS
Snapshot.
Background
Products
Financials
Major Developments
Contact Details
Zhejiang Huahai Pharmaceuticals
Snapshot.
Background

Products
Contact Details
Cyprus
Medochemie
Snapshot.
Background
Products
Contact Details
Egypt
EIPICo
Snapshot.
Background
Products
Contact Details
France
BioAlliance Pharma
Snapshot.
Background
Financials
Major Developments
Contact Details
Germa ny
Alfred E Tiefenbacher (AET)
Snapshot.
Background
Products
Major developments
Contact Details
Fresenius Kabi
Snapshot.
Background
Products
Financials
Major Developments
Contact Details
Greece
Genepharm
Snapshot.
Background
Products
Contact Details
Pharmathen
Snapshot.
Background
Products
Financials
Contact Details
India
Alembic.
Snapshot.
Background

Products
Financials
Major Developments
Contact Details
Alkem
Snapshot.
Background
Products
Major Developments
Contact Details
Bafna Pharmaceuticals
Snapshot.
Background
Products
Financials
Major Developments